Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.
Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks. Pignolet B, et al. Among authors: ongagna jc. Neurology. 2016 Dec 6;87(23):2491-2494. doi: 10.1212/WNL.0000000000003401. Epub 2016 Nov 4. Neurology. 2016. PMID: 27815407 Clinical Trial. No abstract available.
A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort.
Outteryck O, Ongagna JC, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet JC, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D; BIONAT Network,; CFSEP. Outteryck O, et al. Among authors: ongagna jc. Eur J Neurol. 2014;21(1):40-8. doi: 10.1111/ene.12204. Epub 2013 Jun 12. Eur J Neurol. 2014. PMID: 23895407 Clinical Trial.
Long-term follow-up of acute partial transverse myelitis.
Bourre B, Zéphir H, Ongagna JC, Cordonnier C, Collongues N, Debette S, Fleury MC, Outteryck O, Hannequin D, Vermersch P, de Seze J. Bourre B, et al. Among authors: ongagna jc. Arch Neurol. 2012 Mar;69(3):357-62. doi: 10.1001/archneurol.2011.949. Arch Neurol. 2012. PMID: 22410443
JC-virus seroconversion in multiple sclerosis patients receiving natalizumab.
Outteryck O, Zéphir H, Salleron J, Ongagna JC, Etxeberria A, Collongues N, Lacour A, Fleury MC, Blanc F, Giroux M, de Seze J, Vermersch P. Outteryck O, et al. Among authors: ongagna jc. Mult Scler. 2014 Jun;20(7):822-9. doi: 10.1177/1352458513505353. Epub 2013 Sep 26. Mult Scler. 2014. PMID: 24072722
Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
Bigaut K, Fabacher T, Kremer L, Ongagna JC, Kwiatkowski A, Sellal F, Ferriby D, Courtois S, Vermersch P, Collongues N, Zéphir H, De Seze J, Outteryck O. Bigaut K, et al. Among authors: ongagna jc. Mult Scler. 2021 Apr;27(5):729-741. doi: 10.1177/1352458520936239. Epub 2020 Jul 9. Mult Scler. 2021. PMID: 32643521
26 results